Cencora | Pharma solutions

We are thrilled to announce that Cencora has been shortlisted as a finalist for the PMEA Awards 2024, in the "Excellence in Engagement through Digital channels and New Technology" category! This recognition reflects our commitment to delivering exceptional digital promotional and educational campaigns that truly resonate with our target audiences. Our entry, the FormularyDecisions Biosimilar Hub, showcases our dedication to empowering healthcare decision makers (HCDMs) with the resources they need to navigate the rapidly evolving biosimilar landscape. As the largest active online HCDM community in the United States, FormularyDecisions is well-positioned to connect HCDMs with valuable biosimilar resources. Over the past three years, we have achieved nearly 500% growth in HCDM activity on the FormularyDecisions platform, successfully creating a comprehensive resource that addresses critical information gaps in biosimilar adoption. Our team has employed a customer-first approach, focusing on clear objectives and systematic strategies to engage our audience effectively. We extend our heartfelt gratitude to our incredible team for their hard work and innovation, and to the judges for recognizing our efforts. This achievement not only underscores our strategic thinking but also reinforces our mission to create healthier futures. Here’s to continuing our journey of excellence in digital engagement! https://lnkd.in/edrczBPe #PMEA2024 #ExcellenceInEngagement #Biosimilars #DigitalInnovation #Healthcare #awards PMGroup Worldwide Ltd

Looking for guidance related to strategic planning, market access, pharmacovigilance, and more? Access expert insights from the PharmaLex team with our new on-demand video library ⤵️ PharmaLex, now part of Cencora, adds a wealth of expertise to our expanding suite of global pharma solutions throughout all stages of the product lifecycle.

Creating healthier futures isn’t just a tagline. It’s a mission being acted upon every day. Read the case study to learn how Indivior, through partnership with Cencora, was able to achieve greater outcomes in their effort to combat the opioid crisis through enhanced copay program design & patient engagement. https://ow.ly/en3m50Uf1sE

EU HTA Webinar – Achieving broad access fast! What will it take for innovative medicines to succeed? Join us for an insightful discussion hosted by The Evidence Base®, as we prepare for the joint clinical assessment (JCA) launching in January 2025. Date: December 3rd, 2024 Moderator: Herbert Altmann, Vice President, Market Access & Healthcare Consulting Europe, Cencora Panelists: - Iga Lipska, Chairwoman of the Board, Health Policy Institute Poland - François Meyer, Independent Consultant - Oriol Solà-Morales, CEO, Health Innovation Technology Transfer Don’t miss this chance to understand how the new JCA will shape patient access to innovative medicines across Europe and discover the critical success factors for implementing the EU HTA Regulation, strategies for leveraging JCA reports, and recommendations for collaboration among stakeholders. Register now to attend or receive the recording: https://lnkd.in/edmXh-5x #EUHTA #HealthcareInnovation #PatientAccess #Cencora #Webinar

Connect with our team at Trade and Channel Strategies 2024, taking place December 10-12, 2024 in Philadelphia, PA. Our expert team will be partnering with other industry leaders to help you better refine your distribution and channel strategies. Learn more about our speaker sessions book some time with us. https://ow.ly/nv3G50Uf0P1

Join us for an insightful event featuring industry leaders discussing Cencora's market strategies, international transition, and the importance of partnerships in pharma! Don’t miss out on shaping the future together. Register now for our Cencora Product Showcase on December 3: https://ow.ly/u2OW50TZFQy

President-elect Donald Trump has nominated Dr. Mehmet Oz, a physician, TV-show host, and former Republican candidate for Senate in Pennsylvania, to lead the Centers for Medicare & Medicaid Services. Read more about this as well as legislative and regulatory updates in today's edition of Health Policy Weekly.

In biopharma, success goes beyond innovation—it's about strategic collaboration. With development costs hitting $2.3 billion and approval rates below 4%, the stakes are high. As new therapies emerge and patents expire, navigating challenges requires expert partners who can help pave the way from lab to patient. https://ow.ly/RXjP50U8EnX

Serving our customers is one of our highest priorities. Recently, team members from our Consumer Products team stepped up in an urgent situation to support a mother and her child in delivering a device they desperately needed. Read the story: https://ow.ly/9SWT50TsxlM

Payer denials can keep your therapies from patients. Watch the video to see how a key team addition can relieve frustration and improve patient access. Watch full video: https://ow.ly/PEhH50U2FUE